{"id":"W4290879625","doi":"10.1200/jco.21.02815","title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Internal medicine; Dexamethasone; Refractory (planetary science); Clinical endpoint; Multiple myeloma; Hazard ratio; Ixazomib; Progression-free survival; Oncology; Surgery; Gastroenterology; Randomized controlled trial; Chemotherapy; Confidence interval; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005246506,0.001161493,0.002015192,0.0003868029,0.0003111609,0.001025198,0.0007889403,0.0007761262,0.00281464],"category_scores_gemma":[0.002441539,0.0003608044,0.002992736,0.0003867183,0.0008203491,0.0007601934,0.0005753565,0.002141802,0.0003147064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139289,"about_ca_system_score_gemma":0.0009835992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006131636,"about_ca_topic_score_gemma":0.001968974,"domain_scores_codex":[0.9980349,0.001408333,0.00009180439,0.0001888461,0.0001238396,0.0001521759],"domain_scores_gemma":[0.9987081,0.000391641,0.0003831894,0.0001207566,0.00006894612,0.0003273372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9619281,0.003176556,0.00333461,0.0005600603,0.00283957,0.00004161648,0.00004973047,0.001013359,0.001584702,0.0001528546,0.001351336,0.02396751],"study_design_scores_gemma":[0.9022892,0.08011453,0.01151402,0.0000952949,0.002269105,0.00009362041,0.0000380481,0.001189117,0.0004903495,0.0004170531,0.001465058,0.00002450956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855998,0.007721082,0.0008384766,0.0006762547,0.0002613534,0.001745271,0.001456428,0.00007695251,0.001624558],"genre_scores_gemma":[0.990688,0.002194438,0.001138635,0.0009963182,0.0002791195,0.001644388,0.002173767,0.00001984288,0.0008655015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005246506,"threshold_uncertainty_score":0.0277465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1882167091889099,"score_gpt":0.47928399839735,"score_spread":0.2910672892084402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}